Apr 11 |
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
|
Apr 9 |
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
|
Apr 4 |
EIGR, ADXN and BROG are among premarket gainers
|
Apr 3 |
Addex stock climbs on launch of new company, Neurosterix
|
Apr 3 |
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
|
Mar 14 |
Addex to Present at the Bio-Europe Spring 2024 Conference
|
Jan 31 |
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
|
Jan 9 |
Addex to Present at the Swiss Equities Baader Conference
|
Jan 5 |
Addex to Present at Biotech Showcase™ 2024
|
Dec 20 |
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
|